Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

समान संसाधन

• Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
  द्वारा: Kazuyuki Yoshizaki, और अन्य
  प्रकाशित: (1989)
• Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
  द्वारा: K. Yoshizaki, और अन्य
  प्रकाशित: (1989)
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
  द्वारा: Norihiro Nishimoto, और अन्य
  प्रकाशित: (2008)
• T cell receptor V gene usage of islet beta cell-reactive T cells is not restricted in non-obese diabetic mice.
  द्वारा: Nobuhiro Nakano, और अन्य
  प्रकाशित: (1991)
• The paradigm of IL-6: from basic science to medicine
  द्वारा: Naka, Tetsuji, और अन्य
  प्रकाशित: (2002)